TNF-alpha antagonists and thalidomide for the management of gastrointestinal Behçet's syndrome refractory to the conventional treatment modalities: A case series and review of the literature
Küçük Resim Yok
Tarih
2015
Yazarlar
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Clinical and Experimental Rheumatology S.A.S.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Objective. Gastrointestinal involvement of Behçet's syndrome is usually treated with glucocorticoids, 5-aminosalicylic acid compounds and azathioprine. However, some patients are refractory to these conventional therapy modalities. In this paper we report our experience on 13 patients with gastrointestinal involvement of Behçet's syndrome who were refractory to the conventional therapy and who were treated with TNF-alpha antagonists and/or thalidomide. Methods. We reviewed the charts of our Behçet's syndrome patients with gastrointestinal involvement and identified those who were treated with TNF-alpha antagonists and/or thalidomide. Demographic features, previous and concomitant drugs, previous surgery, time to remission and duration of remission were tabulated. We also performed a systematic review of publications on gastrointestinal involvement of Behçet's syndrome patients treated with TNF-alpha antagonists and/or thalidomide. Results. Among our 64 patients with gastrointestinal involvement of Behçet's syndrome, we identified 13 (20%) (7 women, 6 men, mean age 27.4 ± 9.4) who had been treated with TNF-alpha antagonists and/or thalidomide. Their previous medications were glucocorticoids (13/13), azathioprine (13/13), 5-aminosalicylic acid derivatives (3/13) and budesonide (1/13). Clinical and endoscopic remission was obtained in 10 patients. One patient died with sepsis. The systematic literature search revealed 91 cases who had used TNF-alpha antagonists and 15 who had used thalidomide. Among the patients who had received TNF-alpha antagonists, clinical remission was obtained in 47/91 patients (51%), while endoscopic remission was observed in 21/46 (45%) who had a control colonoscopy. Conclusion. One fifth of our Behçet's syndrome patients with gastrointestinal involvement were refractory to conventional treatment modalities. Remission was obtained with TNF-alpha antagonists and/or thalidomide in about 75 % of the cases. © Clinical and Experimental Rheumatology 2015.
Açıklama
Anahtar Kelimeler
Adalimumab; Behçet's Disease; Behçet's Syndrome; Etanercept; Inflammatory Bowel Disease; Infliximab; Intestinal Involvement; Management; Thalidomide, 5 Acetamidosalicylic Acid; 5 Acetamidosalicylic Acid Derivative; Adalimumab; Azathioprine; Budesonide; Canakinumab; Colchicine; Cyclophosphamide; Cyclosporin A; Etanercept; Glucocorticoid; Infliximab; Mercaptopurine; Mesalazine; Methotrexate; Recombinant Interleukin 1 Receptor Blocking Agent; Salazosulfapyridine; Thalidomide; Tumor Necrosis Factor Alpha Inhibitor; Unclassified Drug; Biological Product; Immunosuppressive Agent; Thalidomide; Tumor Necrosis Factor Alpha; Adolescent; Adult; Article; Behcet Disease; Case Study; Cause Of Death; Child; Clinical Article; Clinical Feature; Colonoscopy; Demography; Disease Duration; Female; Gastrointestinal Behcet Syndrome; Gastrointestinal Disease; Gastrointestinal Symptom; Hemicolectomy; Human; Male; Medical Record Review; Middle Aged; Priority Journal; Remission; Sepsis; Systematic Review; Treatment Response; Young Adult; Antagonists And Inhibitors; Behcet Syndrome; Complication; Gastrointestinal Diseases; Immunology; Infant; Preschool Child; Treatment Outcome; Adolescent; Adult; Behcet Syndrome; Biological Products; Child; Child, Preschool; Female; Gastrointestinal Diseases; Humans; Immunosuppressive Agents; Infant; Male; Middle Aged; Remission Induction; Thalidomide; Treatment Outcome; Tumor Necrosis Factor-Alpha; Young Adult
Kaynak
Clinical and Experimental Rheumatology
WoS Q Değeri
Scopus Q Değeri
Q2
Cilt
33
